Current Event 

Overview 
Register
Day 1
Day 2
Short Course 
Hotel & Travel
PDF Download
Sponsor/Exhibit
Posters 
Press Pass 
Request Brochure 

DFX mini Banner  

Web Podcasts 

 

 

 

 

 

 

 

 

 


Corporate Sponsor:
 


NuGen 


Lead Sponsoring Publications:
 


Bio-IT World 

GEN 

Nature 

Science AAAS 

The Scientist 


Sponsoring Publications:
 


Drug Discovery News 

Genome Technology 

Insight Pharma Reports 

PharmaVoice 


Media Partner:
 


 

 

 

 


Web Partners:
 


Biospace 

Genomeweb Logo 


Innovative Sample Prep and Target Enrichment in Clinical Diagnostics - 2012 - Day 2

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

Thursday, April 19

8:00 am Breakout Discussions (coffee will be served) 

Sample Prep for Pathogen Detection 

Cicely Washington, Ph.D., Technical Leader, Ibis Biosciences, Inc., a subsidiary of Abbott Molecular 

Sample Prep in Mass Spectrometry 

Randall W. Nelson, Ph.D., Director, The Molecular Biomarkers Laboratory, The Biodesign Institute, Arizona State University 

Nucleic Acid Extraction 

Martin Siaw, Ph.D., Associate Scientific Director (R&D), Advanced Sequencing, Quest Diagnostics Nichols Institute – new moderator 

Pre-Analytical Issues in Mass Spectrometry Applications 

8:55 Chairperson’s Remarks 

Jeff Whiteaker, Ph.D., Director of Proteomics, Paulovich Laboratory, Fred Hutchinson Cancer Research Center 

9:00 Why Are Non-Targeted Metabolomics and Proteomics Biased?

Uwe Christians, M.D., Ph.D., Professor, Department of Anesthesiology, University of Colorado Denver; Professor of Experimental and Clinical Pharmacology and Toxicology,

Institut für Pharmakologie, Medizinische Hochschule Hannover.

Current technologies capture only a part of the metabolome and/or proteome and therefore produce inherently biased results. This brings up the question of whether or not screening for changes in known metabolic and signaling pathways using a set of targeted validated, quantitative multiplexing assays would be a more robust and reliable approach.

9:30 SISCAPA: Combining Immunoaffinity and Mass Spectrometry in a Universal Platform for Sensitive, Specific Measurement of Protein Biomarkers

N. Leigh Anderson, Ph.D., Founder and CEO of the Plasma Proteome Institute

Translation of protein biomarker candidates into clinical diagnostics depends on efficient generation of reliable specific assays. Mass spectrometry of proteotypic peptides provides major advantages over classical immunoassays in terms of specificity, internal standardization and multiplexing, while the enrichment of selected signature peptides by anti-peptide antibodies (SISCAPA) provides the necessary sensitivity and sample throughput. Relevant diagnostic assay examples will be discussed

10:00 Sponsored Presentation (Opportunity Available) 

10:30 Networking Coffee Break with Poster Viewing

11:00 Quantitative Proteomics Using Peptide Immunoaffinity Enrichment Coupled with Mass Spectrometry

Jeff Whiteaker, Ph.D., Director of Proteomics, Paulovich Laboratory, Fred Hutchinson Cancer Research Center

The use of quantitative targeted mass spectrometry for protein assays has grown tremendously in recent years. The largest limitation to more widespread use is the limited sensitivity in complex matrices. We have implemented a technique using immunoaffinity enrichment of peptides with quantification by mass spectrometry to make assays for a wide range of proteins. The assays have many advantages including improved sensitivity, absolute specificity, relatively less time and money required for development, high levels of multiplexing, and good performance characteristics. This presentation will provide an overview of the development and implementation of these assays for biomarker verification.

11:30 Using High Throughput Mass Spectrometric Immunoassay (MSIA) in Biomarker Development

Randall W. Nelson, Ph.D., Director, The Molecular Biomarkers Laboratory, The Biodesign Institute, Arizona State University

Biomarker development requires the implementation of progressively standardized and increasingly rigorous analytical technologies. Regarding proteins, such technologies must be; 1) Highly accurate, sensitive and reproducible, 2) Responsive to large concentration differences and disease-specific qualitative variations, and, 3) Employed at rates sufficient to economically accommodate large clinical sample sets. Here, we present one such technology, mass spectrometric immunoassay (MSIA) and illustrate its use in the development of multi-analyte biosignatures of type 2 diabetes and related cardiovascular diseases.

12:00 pm Close of the conference


By Series:
By Region: